Bioequivalence of mirabegron 50 mg extended release Tablet [Design Issues]

posted by Ibrahim Komeil – Egypt, 2021-02-20 11:36 (211 d 16:06 ago) – Posting: # 22218
Views: 1,086

Dear All
I had performed a 2X2 crossover study between test and reference product of mirabegron 50 mg under fasting conditions where 34 volunteers were completed the study.

Knowing that I couldn't find an accurate data for intrasubject variability of Mirabegnon. The results showed a very high unexpected intra-subject variability as following:
Cmax: 73.8451%, AUCt: 67.6524%
I calculated study power too and it results as following:
Cmax: 38.45% and AUCt: 42.38%

Therefore, a sequential two stage study won't be applicable in that condition. My question is: If i repeat the aforementioned study again, shall i follow a partial replicated cross over design or full replicated cross over design?

My second: Shall i follow RASBE or unscaled BE limits ?

Thanks in advance

Complete thread:

 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time: Monday 04:43 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz